TFEB Polypeptide Upregulation for Lysosomal Dysfunction Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Lysosomal dysfunction leads to the accumulation of undegraded molecules, contributing to various pathological conditions such as lysosomal storage diseases and age-related disorders, with existing therapies being limited in efficacy, especially in the central nervous system and certain cell types.
Innovation Solution
Increasing transcription factor EB (TFEB) polypeptide levels within cells using specific organic compounds to enhance lysosomal biogenesis, autophagy, and lysosomal exocytosis, thereby improving cellular recycling and reducing disease symptoms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing therapies are used to treat lysosomal dysfunction, then some therapeutic effect is achieved, but efficacy is limited especially in the central nervous system and certain cell types
Solution Approach 1:
The patent uses TFEB as an intermediary molecule that, when activated by small compounds, mediates the upregulation of lysosomal and autophagy-related genes. This intermediary approach allows indirect treatment of lysosomal dysfunction by enhancing the cell's own lysosomal biogenesis and function, thereby improving therapeutic efficacy where direct therapies fail, particularly in the central nervous system.
Solution Approach 2:
The patent employs small-molecule compounds that change the nuclear localization parameter of TFEB by promoting its translocation from the cytoplasm to the nucleus. This parameter change (subcellular localization) triggers a cascade of gene expression changes that enhance lysosomal function and autophagy, providing a mechanism to overcome tissue-specific therapeutic limitations.
2Reliability
If TFEB is activated to increase lysosomal biogenesis and autophagy, then cellular recycling is improved and disease symptoms are reduced, but the complexity of the therapeutic approach increases
Solution Approach 1:
The patent activates TFEB to enable cells to self-regulate their own lysosomal function and autophagy processes. By upregulating lysosomal biogenesis and autophagy-related genes through TFEB activation, the cell's inherent recycling and degradation systems are enhanced without requiring external complex intervention, thereby improving disease treatment efficacy while maintaining relative therapeutic simplicity.
Data Source
AI summary
This document provides methods and materials for increasing TFEB polypeptide levels. For example, compounds (e.g., organic compounds) having the ability to increase TFEB polypeptide levels within cells and/or within a nucleus of cells, formulations containing compounds having the ability to increase TFEB polypeptide levels within cells and/or within a nucleus of cells, methods for making compounds having the ability to increase TFEB polypeptide levels within cells and/or within a nucleus of cells, methods for making formulations containing compounds having the ability to increase TFEB polypeptide levels within cells and/or within a nucleus of cells, methods for increasing TFEB polypeptide levels within cells and/or within a nucleus of cells, and methods for treating mammals (e.g., humans) having a condition responsive to an increase in TFEB polypeptide levels are provided.